Use of Donepezil for Treatment of Cocaine Dependence (NCT00467389) | Clinical Trial Compass
CompletedPhase 2
Use of Donepezil for Treatment of Cocaine Dependence
United States12 participantsStarted 2007-02
Plain-language summary
The purpose of this study is to determine the safety of intravenous cocaine in subjects receiving oral donepezil.
Who can participate
Age range18 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Non-treatment seeking, experienced cocaine users, who have used cocaine by smoking or intravenous injection within the four weeks prior to screening, and must supply a cocaine-positive urine obtained within four weeks of entry into the study.
Exclusion Criteria:
* Shows signs of psychostimulant toxicity, or has a history of a medical adverse reaction to cocaine or other psychostimulants, including loss of consciousness, chest pain, cardiac ischemia, or seizure.
* Has a current psychiatric disorder other than drug abuse or dependence or dementia.
* Meets the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for dependence to opiates, benzodiazepines, alcohol, or other sedative-hypnotics.
* Has received opiate-substitution therapy (methadone or buprenorphine) within two months prior to enrollment.
* Has current or past history of seizure disorder, including alcohol- or psychostimulant- related seizures, or family history of seizure disorder.
* Has a diagnosis of adult asthma, or chronic obstructive pulmonary disease, including a history of acute asthma within the past two years, and those with current or recent (with the past two years) treatment with an inhaled or oral beta-adrenergic agonist.
* Has had head trauma that resulted in neurological sequelae.
* Has an unstable medical condition, which, in the judgement of investigators, would make participation hazardous.